NOV.DE Novo Nordisk A/S
Company Analysis
Latest News
🟢 Novo Nordisk is trading 4% up today after sharp multi-session decline
Novo Nordisk is trading 3.96% up now at €40.71 after a sharp multi-session decline. - No new company-specific announcement or analyst action dated August 10,...
Novo Nordisk Beat Expectations and Raised Its Outlook — So Why Are Investors Still Heading for the Exit?
Shares of Novo Nordisk slid to €39.70, down 1.8%, extending a bruising week-long selloff that has erased roughly 12% since July 28. The Danish drugmaker...
Novo Nordisk Beat Expectations and Raised Its Outlook — So Why Are Investors Still Heading for the Exit?
Shares of Novo Nordisk slid to €39.70, down 1.8%, extending a bruising week-long selloff that has erased roughly 12% since July 28. The Danish drugmaker...
🟢 Novo Nordisk is trading 4.25% up today as investors reassess Q2 results and raised 2026 outlook
Novo Nordisk's stock is experiencing a 4.25% rebound today, trading at €40.83, as investors re-evaluate the company's raised 2026 adjusted sales and operating...
🟢 Novo Nordisk is trading 3.1% up today on relief bounce after Wegovy earnings selloff
Novo Nordisk is trading 3.1% up at €40.36 as it rebounds from a sharp selloff following its Q2 earnings report. • The stock faced pressure on August 5 after a...
🔴 Novo Nordisk Dips 3.5% as Q2 Earnings Reveal Wegovy Sales Miss, CagriSema Setback
Novo Nordisk is trading at €39.70, down 3.5% today. The decline follows the company's Q2 2026 earnings, where investors reacted to a narrow sales miss for its...
🔴 Novo Nordisk is trading 5.2% down today on sector pressure and profit-taking
Novo Nordisk is trading 5.2% down today at €41.88 following a sharp pullback that aligns with broader weakness in the healthcare sector. • The move appears...
Novo Nordisk sues Eli Lilly, alleging false Wegovy and Ozempic comparisons
Novo Nordisk filed a lawsuit against Eli Lilly in a New Jersey federal court for false and misleading advertising. The complaint targets national campaigns for...
🟢 Novo Nordisk is trading 3.2% up today in a rebound from recent weakness
Novo Nordisk is trading 3.2% up at €44.10 in a rebound from recent weakness, outperforming a healthcare sector that is currently under pressure. • The move...
Novo Nordisk reports positive data for denecimig, citing long-term phase 3 results
Novo Nordisk announced positive results from the phase 3 FRONTIER4 extension study for denecimig (Mim8). The data, presented at the International Society on...
Novo Nordisk tests Vivani’s semaglutide implant to replace weekly injections
Novo Nordisk partnered with Vivani Medical to evaluate NPM-139, an implantable device for delivering semaglutide. The implant utilizes NanoPortal technology...
Novo Nordisk secures Medicare coverage for Wegovy, expanding access for millions
Medicare begins coverage for specific GLP-1 weight-loss medications on July 1, 2026. This expansion provides millions of eligible seniors access to treatments...